Rituximab and Canakinumab Use During Lactation: No Detectable Serum Levels in Breastfed Infants.

Bosshard, Nicole; Zbinden, Astrid; Eriksson, Klara Kristin; Förger, Frauke (2021). Rituximab and Canakinumab Use During Lactation: No Detectable Serum Levels in Breastfed Infants. Rheumatology and therapy, 8(2), pp. 1043-1048. Springer 10.1007/s40744-021-00313-z

Preview

Text FFOE2.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (229kB) | Preview

INTRODUCTION

In breastfeeding patients with chronic inflammatory rheumatic diseases, a postpartum flare may require the use of biologics. However, data on the safety of biologics during lactation are scarce, potentially impeding the decision-making process.

CASE SERIES

We report two cases of women in whom treatment with a monoclonal IgG antibody (rituximab or canakinumab) was indicated during the lactation period. In both cases, breastfeeding was continued, and drug levels in the mother's serum, in serial breast milk samples and in the infant's serum were measured. Both rituximab and canakinumab showed minimal drug concentrations in breast milk and no detectable levels in the infants' sera.

CONCLUSION

The lack of detectable levels of rituximab and canakinumab in the sera of breastfed infants reflects the poor oral bioavailability of these biologics and helps to promote their use in breastfeeding patients.

Interest & Impact

Downloads

48 since deposited on 03 Dec 2021
15 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item